Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Walter Fiedler, Hubert Serve, Hartmut Döhner, Michael Schwittay, Oliver G. Ottmann, Anne-Marie O'Farrell, Carlo L. Bello, Randy Allred, William C. Manning, Julie M. Cherrington, Sharianne G. Louie, Weiru Hong, Nicoletta M. Brega, Giorgio Massimini, Paul Scigalla, Wolfgang E. Berdel, Dieter K. Hossfeld

Blood (2005) 105 (3): 986–993.

https://doi.org/10.1182/blood-2004-05-1846

Published: 2005

Journal Articles

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

Kevin W. H. Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, Ajia R. Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, Michael C. Heinrich

Blood (2004) 104 (13): 4202–4209.

https://doi.org/10.1182/blood-2003-10-3381

Published: 2004

Journal Articles

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Francis J. Giles, Alison T. Stopeck, Lewis R. Silverman, Jeffrey E. Lancet, Maureen A. Cooper, Alison L. Hannah, Julie M. Cherrington, Anne-Marie O'Farrell, Helene A. Yuen, Sharianne G. Louie, Weiru Hong, Jorge E. Cortes, Srdan Verstovsek, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian, Judith E. Karp

Blood (2003) 102 (3): 795–801.

https://doi.org/10.1182/blood-2002-10-3023

Published: 2003

Journal Articles

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Theresa J. Ngai, Sharianne G. Louie, Kevin W. H. Yee, Lily M. Wong, Weiru Hong, Leslie B. Lee, Ajia Town, Beverly D. Smolich, William C. Manning, Lesley J. Murray, Michael C. Heinrich, Julie M. Cherrington

Blood (2003) 101 (9): 3597–3605.

https://doi.org/10.1182/blood-2002-07-2307

Published: 2003

Journal Articles

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Kevin W. H. Yee, Anne Marie O'Farrell, Beverly D. Smolich, Julie M. Cherrington, Gerald McMahon, Cecily L. Wait, Laura S. McGreevey, Diana J. Griffith, Michael C. Heinrich

Blood (2002) 100 (8): 2941–2949.

https://doi.org/10.1182/blood-2002-02-0531

Published: 2002

Journal Articles

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

Albert T. Liao, May B. Chien, Narmada Shenoy, Dirk B. Mendel, Gerald McMahon, Julie M. Cherrington, Cheryl A. London

Blood (2002) 100 (2): 585–593.

https://doi.org/10.1182/blood-2001-12-0350

Published: 2002

Journal Articles

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

Beverly D. Smolich, Helene A. Yuen, Kristina A. West, Francis J. Giles, Maher Albitar, Julie M. Cherrington

Blood (2001) 97 (5): 1413–1421.

https://doi.org/10.1182/blood.V97.5.1413

Published: 2001

NARROW

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

Email alerts

ASH Publications

American Society of Hematology

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only